[1] Vogel A , Martinelli E . Updated treatment recommendations for hepatocellular carcinoma (HCC) from clinical practice guidelines. Ann Oncol, 2021,32(4):801-805. [2] Nderitu P , Bosco C , Garmo H , et al. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish amoris cohort. Int Jo Cancer, 2017,141(6):1148-1160. [3] Poynard T , Peta V , Deckmyn O , et al. Lcr1 and lcr2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Aliment Pharmacol Ther, 2019,43(3):308-320. [4] Kono Y , Lyshchik A , Cosgrove D , et al. Contrast enhanced ultrasound (ceus) liver imaging reporting and data system (li-rads): the official version by the American college of radiology (ACR). Ultraschall Med, 2017, 38(1):85-86. [5] Vernuccio F , Cannella R , Meyer M , et al. LI-RADS: Diagnostic performance of hepatobiliary phase hypointensity and major imaging features of lr-3 and lr-4 lesions measuring 10–19 mm with arterial phase hyperenhancement. AJR, 2019, 213(2):57-65. [6] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792. [7] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会, 等.原发性肝癌规范化病理诊断指南(2015年版).中华肝脏病杂志,2015,23(5):321-327. [8] 邢飞, 陆健, 张涛,等. 肝硬化背景下MRI肝脏影像报告和数据系统LR-2,LR-3,LR-4类结节的变化与预后. 中华放射学杂志, 2018, 52(4):272-276. [9] Lee S M , Lee J M, Ahn S J , et al. LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium–enhanced MRI. Radiology, 2019, 292(3):655-663. [10] 张学秀,王立峰,金磊, 等.原发性胆汁性肝硬化患者发生肝癌危险因素的研究进展.中华肝脏病杂志,2015,23(2):147-149. [11] Persson EC , Schwartz LM , Park Y , et al. Alcohol consumption, folate intake, hepatocellular carcinoma, and liver disease mortality. Cancer Epidemiol Biomarkers Prev, 2013, 22(3):415-421. [12] Moriya A , Iwasaki Y , Ohguchi S , et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol, 2015, 62(4):921-927. [13] 张利利,李玉芳,张驰, 等.乙型肝炎肝硬化合并2型糖尿病发生原发性肝癌的风险研究.中华肝脏病杂志,2019,27(10):788-792. [14] Wang Y, He HY, Chang JT, et al. Mueller matrix microscope: a quantitative tool to facilitate detections and fibrosis scorings of liver cirrhosis and cancer tissues. J Biomed Opt, 2016, 21(7):711-716. [15] Chen XQ , Fan W , Liu YM , et al. The contribution of serum hepatitis b virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta-analyses. Oncotarget, 2016, 7(31):49299-49309. [16] Wu JL , Xiang ZY , Bai L , et al. Diagnostic value of serum pivka-ii levels for bclc early hepatocellular carcinoma and correlation with HBV DNA. Cancer Biomark, 2018, 23(2):235-242. [17] Tanaka Y , Esumi M , Shikata T . Frequent integration of hepatitis B virus DNA in noncancerous liver tissue from hepatocellular carcinoma patients. J Med Virol, 2010, 26(1):7-14. [18] Ren Y D , Ye Z S , Yang L Z , et al. Fecal microbiota transplantation induces HBeAg clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology, 2016, 65(5):1765-1768. [19] Bassendine M F , Seta L D , Salmeron J , et al. Incidence of hepatitis B virus infection in alcoholic liver disease, HBsAg negative chronic active liver disease and primary liver cell cancer in Britain. Liver, 2010, 3(2):65-70. [20] Bai H , Liu H , Chen X , et al. Influence of age and HBeAg status on the correlation between HBV DNA and hepatic inflammation and fibrosis in chronic hepatitis B patients. Dig Dis Sci, 2013, 58(5):1355-1362. |